Can an asthma drug shrink nasal polyps? a major trial seeks answers

NCT ID NCT03085797

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether mepolizumab, an injectable antibody that calms a type of immune cell, can reduce nasal polyp size and improve breathing when added to standard nasal spray therapy. About 400 adults with severe bilateral nasal polyps will receive either mepolizumab or a placebo every four weeks for a year, alongside daily mometasone furoate nasal spray. The study measures changes in polyp size and nasal blockage scores to see if the drug offers meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mepolizumab, a monoclonal antibody that blocks interleukin-5, given as a subcutaneous injection every 4 weeks
What this could lead to: If it works, this could offer a new add-on treatment option for people with severe nasal polyps who still have symptoms despite standard therapy.
What could go wrong: This is a phase 3 trial, so earlier results were promising but not definitive. The drug may not improve symptoms enough to justify its use, and side effects from blocking part of the immune system are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasal cavity polyp

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASAL POLYPS

More trials for these conditions

Other studies related to the condition(s) this trial covers.